The association of platelet count with clinicopathological significance and prognosis in renal cell carcinoma: A systematic review and meta-analysis

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Gu, Liangyou ^a   Li, Hongzhao ^a   Gao, Yu ^a   Ma, Xin ^a   Chen, Luyao ^a   Li, Xintao ^a   Zhang, Yu ^a   Fan, Yang ^a   Zhang, Xu ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE ASSOCIATION; DISTANT METASTASIS; HUMAN; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; TUMOR VOLUME; BLOOD; CARCINOMA, RENAL CELL; DISEASE FREE SURVIVAL; INFLAMMATION; META ANALYSIS; METASTASIS; PATHOLOGY; PROGNOSIS;

CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; HUMANS; INFLAMMATION; NEOPLASM METASTASIS; PLATELET COUNT; PROGNOSIS;

EID: 84957557999     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125538     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90. doi: 10.3322/caac.20107 PMID: 21296855
2. Crispen PL, Breau RH, Allmer C, Lohse CM, Cheville JC, Leibovich BC, et al. (2011) Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: Indications and recommendations for surgical templates. Eur Urol 59: 18-23. doi: 10.1016/j.eururo.2010.08.042 PMID: 20933322
3. Moch H, Artibani W, Delahunt B, Ficarra V, Knuechel R, Montorsi F, et al. (2009) Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol 56: 636-643. doi: 10.1016/j.eururo. 2009.06.036 PMID: 19595500
4. Lee SE, Byun SS, Han JH, Han BK, Hong SK (2006) Prognostic significance of common preoperative laboratory variables in clear cell renal cell carcinoma. BJU Int 98: 1228-1232. PMID: 17034508
5. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89: 1028-1030. PMID: 12966420
6. Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC (2006) Evaluation of an inflammation- based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer 94: 637-641. PMID: 16479253
7. Wu Y, Fu X, Zhu X, He X, Zou C, Han Y, et al. (2011) Prognostic role of systemic inflammatory response in renal cell carcinoma: A systematic review and meta-analysis. J Cancer Res Clin Oncol 137: 887-896. doi: 10.1007/s00432-010-0951-3 PMID: 20878529
8. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 6: E1000097. doi: 10.1371/journal.pmed.1000097 PMID: 19621072
9. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. (2000) Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008-2012. PMID: 10789670
10. Jacobsen J, Grankvist K, Rasmuson T, Ljungberg B (2002) Prognostic importance of serum vascular endothelial growth factor in relation to platelet and leukocyte counts in human renal cell carcinoma. Eur J Cancer Prev 11: 245-252. PMID: 12131658
11. Inoue K, Kohashikawa K, Suzuki S, Shimada M, Yoshida H (2004) Prognostic significance of thrombocytosis in renal cell carcinoma patients. Int J Urol 11: 364-367. PMID: 15157203
12. Bensalah K, Leray E, Fergelot P, Rioux-Leclercq N, Tostain J, Guille F, et al. (2006) Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 175: 859-863. PMID: 16469566
13. Karakiewicz PI, Trinh QD, Lam JS, Tostain J, Pantuck AJ, Belldegrun AS, et al. (2007) Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality. Eur Urol 52: 1428-1436. PMID: 17420085
14. Pflanz S, Brookman-Amissah S, Roigas J, Kendel F, Hoschke B, May M (2008) Impact of macroscopic tumour necrosis to predict survival of patients with surgically resected renal cell carcinoma. Scand J Urol Nephrol 42: 507-513. doi: 10.1080/00365590802460633 PMID: 19031267
15. Brookman-Amissah S, Kendel F, Spivak I, Pflanz S, Roigas J, Klotz T, et al. (2009) Impact of clinical variables on predicting disease-free survival of patients with surgically resected renal cell carcinoma. BJU Int 103: 1375-1380. doi: 10.1111/j.1464-410X.2008.08233.x PMID: 19040527
16. Brookman-May S, May M, Ficarra V, Kainz MC, Kampel-Kettner K, Kohlschreiber S, et al. (2013) Does preoperative platelet count and thrombocytosis play a prognostic role in patients undergoing nephrectomy for renal cell carcinoma? Results of a comprehensive retrospective series. World J Urol 31: 1309-1316. doi: 10.1007/s00345-012-0931-0 PMID: 22903790
17. Fox P, Hudson M, Brown C, Lord S, Gebski V, De Souza P, et al. (2013) Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. Br J Cancer 109: 147-153. doi: 10. 1038/bjc.2013.300 PMID: 23778526
18. Yap NY, Ng KL, Ong TA, Pailoor J, Gobe GC, Ooi CC, et al. (2013) Clinical prognostic factors and survival outcome in renal cell carcinoma patients-A Malaysian single centre perspective. Asian Pac J Cancer Prev 14: 7497-7500. PMID: 24460324
19. Yang YQ, Chen J (2014) Predictive role of vascular endothelial growth factor polymorphisms in the survival of renal cell carcinoma patients. Genet Mol Res 13: 5011-5017. doi: 10.4238/2014.July.4.16 PMID: 25062489
20. Gogus C, Baltaci S, Filiz E, Elhan A, Beduk Y (2004) Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma. Urology 63: 447-450. PMID: 15028435
21. Lehmann J, Retz M, Nurnberg N, Schnockel U, Raffenberg U, Krams M, et al. (2004) The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma. Cancer 101: 1552-1562. PMID: 15378494
22. Erdemir F, Kilciler M, Bedir S, Ozgok Y, Coban H, Erten K (2007) Clinical significance of platelet count in patients with renal cell carcinoma. Urol Int 79: 111-116. PMID: 17851278
23. Ramsey S, Lamb GW, Aitchison M, McMillan DC (2008) Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int 101: 959-963. doi: 10.1111/j.1464-410X.2007.07363.x PMID: 18190639
24. Dae SC, Se JK, Soo HL, Hyun SA, Young SK, Sun IK (2011) Prognostic significance of preoperative Creactive protein elevation and thrombocytosis in patients with non-metastatic renal cell carcinoma. Korean J Urol 52: 104-109. doi: 10.4111/kju.2011.52.2.104 PMID: 21379426
25. Suppiah R, Shaheen PE, Elson P, Misbah SA, Wood L, Motzer R, et al. (2006) Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 107: 1793-1800. PMID: 16983701
26. Cho KS, Choi YD, Kim SJ, Kim CI, Chung BH, Seong do H, et al. (2008) A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma. Yonsei Med J 49: 451-458. doi: 10. 3349/ymj.2008.49.3.451 PMID: 18581596
27. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J Clin Oncol 27: 5794-5799. doi: 10. 1200/JCO.2008.21.4809 PMID: 19826129
28. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, et al. (2011) Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol 22: 1048-1053. doi: 10.1093/annonc/mdq563 PMID: 21115604
29. Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, et al. (2013) Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 108: 887-900. doi: 10.1038/bjc.2012.548 PMID: 23462807
30. Dirican A, Kucukzeybek Y, Somali I, Erten C, Demir L, Can A, et al. (2013) The association of hematologic parameters on the prognosis of patients with metastatic renal cell carcinoma. J BUON 18: 413-419. PMID: 23818354
31. Yildiz I, Sen F, Kilic L, Ekenel M, Ordu C, Kilicaslan I, et al. (2013) Prognostic factors associated with the response to sunitinib in patients with metastatic renal cell carcinoma. Curr Oncol 20: E546-553. doi: 10.3747/co.20.1596 PMID: 24311955
32. Park JY, Lee JL, Baek S, Eo SH, Go H, Ro JY, et al. (2014) Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor- targeted therapy. Hum Pathol 45: 1437-1444. doi: 10.1016/j.humpath.2014.02.019 PMID: 24784922
33. Stenman M, Laurell A, Lindskog M (2014) Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma. Med Oncol 31: 841. doi: 10.1007/s12032-014-0841-7 PMID: 24477648
34. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16. PMID: 17555582
35. Levin J, Conley CL (1964) Thrombocytosis associated with malignant disease. Arch Intern Med 114: 497-500. PMID: 14184638
36. Verheul HM, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MF, Pinedo HM (2000) Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 96: 4216-4221. PMID: 11110694
37. Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A, Papavassiliou E, et al. (1996) Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A 93: 10589-10594. PMID: 8855222
38. Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M (2006) Impact of thrombocytosis and Creactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol 13: 1365-1370. PMID: 17083384
39. Bromwich EJ, McArdle PA, Canna K, McMillan DC, McNicol AM, Brown M, et al. (2003) The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer 89: 1906-1908. PMID: 14612901
40. Sutton AJ, Song F, Gilbody SM, Abrams KR (2000) Modelling publication bias in meta-analysis: A review. Stat Methods Med Res 9: 421-445. PMID: 11191259
41. Zwahlen M, Renehan A, Egger M (2008) Meta-analysis in medical research: Potentials and limitations. Urol Oncol 26: 320-329. doi: 10.1016/j.urolonc.2006.12.001 PMID: 18452828